An Extended History of Trust
PBM Pharmaceuticals acquired the rights to Donnatal products from Wyeth Laboratories in 2001. Following the acquisition, the response from
the medical community and IBS patients for Donnatal Extentabs was overwhelming.
Both physicians and patients contacted
PBM, expressing their appreciation for maintaining Donnatal Extentabs in the marketplace.
All Day, All Night... Only Donnatal Extentabs
Donnatal Extentabs are an extended release, combination antispasmodic therapy with a history of
trust for more than 25 years.
There have been more than 435 million patient days of combination antispasmodic therapy since 1991. (1)
Of all the options available in this type of therapy, only Donnatal Extentabs provide gradual dissolution over 12 hours,
distinctively longer than immediate release tablets. (2)
The Benefits of Extended Release
The nighttime benefit afforded by extended release is important to the IBS sufferers whose symptoms occurring through the night
prevent a full night's rest. Without proper rest at night, their quality of life is affected as well as their
ability to be productive in school or in the workplace.
1) Source Prescription Audit (SPA), Verispan, November 2002.
2) Data on File, PBM Pharmaceuticals. |
